Esperion Therapeutics, Inc. — Director's Dealing 2021

Jan 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2021-01-28

Reporting Person: Hall Ashley (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-28	Common Stock	A	7000	—	Acquired	22500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-28	Stock Option (right to buy)	$32.12	A	31000	Acquired	2031-01-28	Common Stock (31000.0)	Direct

Footnotes

F1: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021.